ARTICLE | Company News
Galapagos, Agency for Innovation by Science and Technology, University of Antwerp, University of Leuven infectious news
February 16, 2015 8:00 AM UTC
Galapagos and the University of Antwerp received EUR2.5 million ($2.8 million) from the Flemish Agency for Innovation by Science and Technology to develop Galapagos’ GLPG1492 to treat methicillin-resistant Staphylococcus aureus (MRSA) infection. The project will also include development of a rapid diagnostic test. The university will perform basic research focusing on further understanding of antibiotic resistance mechanisms. This year, Galapagos plans to begin a Phase I trial of GLPG1492, a narrow-spectrum antibiotic, in healthy volunteers. ...